0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Drug‐Induced Liver Injury Caused by Metamizole: Identification of a Characteristic Injury Pattern

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          Background and Aims

          Drug‐induced liver injury (DILI) due to metamizole has gained increasing attention. Causality assessment remains a challenge, especially in patients with co‐medications. We therefore aimed to further characterise metamizole DILI cases.

          Methods

          The data of patients with metamizole intake from our prospective study on acute liver injury with potential drug‐related causes were analysed. Diagnosis and causality assessment were based on a thorough work‐up and long‐term follow‐up.

          Results

          DILI was associated with metamizole in 61 of 324 DILI patients (prevalence 18.8%). A highly characteristic clinical pattern was observed in 43 of the 61 patients, characterised by marked elevation of transaminases peaking at the time of DILI recognition and a more pronounced increase of bilirubin within the first 3 days of clinical presentation. Patients fitting this picture had higher rates of jaundice, coagulopathy, and acute liver failure, however outcomes did not differ significantly when compared to non‐metamizole DILI and autoimmune hepatitis (AIH) patients. Overall, fatal adverse outcomes defined by death or liver transplantation were observed in 13.1% of metamizole DILI patients. On multivariate analysis, only aspartate aminotransferase (AST) and INR were independently associated with a fatal adverse outcome. INR, in particular, performed better than Hy's law, bilirubin, transaminases, and the model for end‐stage liver disease (MELD), with a c‐statistic of 0.85 (95% CI: 0.70–1.0). At a cut‐off of ≥ 2.1, sensitivity and specificity for a fatal adverse outcome were 75% and 96%, respectively.

          Conclusions

          Metamizole DILI can present with a characteristic pattern that can help clinicians to identify metamizole as the causative agent. Outcome, however, is not associated with this clinical picture and should rather be predicted by INR at onset.

          Trial Registration

          ClinicalTrials.gov identifier: NCT 02353455

          Related collections

          Most cited references33

          • Record: found
          • Abstract: found
          • Article: not found

          EASL Clinical Practice Guidelines: Drug-induced liver injury

          Idiosyncratic (unpredictable) drug-induced liver injury is one of the most challenging liver disorders faced by hepatologists, because of the myriad of drugs used in clinical practice, available herbs and dietary supplements with hepatotoxic potential, the ability of the condition to present with a variety of clinical and pathological phenotypes and the current absence of specific biomarkers. This makes the diagnosis of drug-induced liver injury an uncertain process, requiring a high degree of awareness of the condition and the careful exclusion of alternative aetiologies of liver disease. Idiosyncratic hepatotoxicity can be severe, leading to a particularly serious variety of acute liver failure for which no effective therapy has yet been developed. These Clinical Practice Guidelines summarize the available evidence on risk factors, diagnosis, management and risk minimization strategies for drug-induced liver jury.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure.

            The term acute liver failure (ALF) is frequently applied as a generic expression to describe patients presenting with or developing an acute episode of liver dysfunction. In the context of hepatological practice, however, ALF refers to a highly specific and rare syndrome, characterised by an acute abnormality of liver blood tests in an individual without underlying chronic liver disease. The disease process is associated with development of a coagulopathy of liver aetiology, and clinically apparent altered level of consciousness due to hepatic encephalopathy. Several important measures are immediately necessary when the patient presents for medical attention. These, as well as additional clinical procedures will be the subject of these clinical practice guidelines.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Simplified criteria for the diagnosis of autoimmune hepatitis.

              Diagnosis of autoimmune hepatitis (AIH) may be challenging. However, early diagnosis is important because immunosuppression is life-saving. Diagnostic criteria of the International Autoimmune Hepatitis Group (IAIHG) were complex and purely meant for scientific purposes. This study of the IAIHG aims to define simplified diagnostic criteria for routine clinical practice. Candidate criteria included sex, age, autoantibodies, immunoglobulins, absence of viral hepatitis, and histology. The training set included 250 AIH patients and 193 controls from 11 centers worldwide. Scores were built from variables showing predictive ability in univariate analysis. Diagnostic value of each score was assessed by the area under the receiver operating characteristic (ROC) curve. The best score was validated using data of an additional 109 AIH patients and 284 controls. This score included autoantibodies, immunoglobulin G, histology, and exclusion of viral hepatitis. The area under the curve for prediction of AIH was 0.946 in the training set and 0.91 in the validation set. Based on the ROC curves, two cutoff points were chosen. The score was found to have 88% sensitivity and 97% specificity (cutoff > or =6) and 81% sensitivity and 99% specificity (cutoff > or =7) in the validation set. A reliable diagnosis of AIH can be made using a very simple diagnostic score. We propose the diagnosis of probable AIH at a cutoff point greater than 6 points and definite AIH 7 points or higher.
                Bookmark

                Author and article information

                Contributors
                sabine.weber@med.uni-muenchen.de
                Journal
                Liver Int
                Liver Int
                10.1111/(ISSN)1478-3231
                LIV
                Liver International
                John Wiley and Sons Inc. (Hoboken )
                1478-3223
                1478-3231
                06 February 2025
                March 2025
                : 45
                : 3 ( doiID: 10.1111/liv.v45.3 )
                : e70012
                Affiliations
                [ 1 ] Department of Medicine II LMU Klinikum Munich Germany
                [ 2 ] Institute of Pathology, Medical Faculty LMU Munich Germany
                Author notes
                [*] [* ] Correspondence:

                Sabine Weber ( sabine.weber@ 123456med.uni-muenchen.de )

                Author information
                https://orcid.org/0000-0001-7077-8078
                https://orcid.org/0000-0001-9983-5136
                Article
                LIV70012 LIVint-24-00890.R3
                10.1111/liv.70012
                11801327
                39912769
                b560b74a-639f-4640-a594-f4135efcf337
                © 2025 The Author(s). Liver International published by John Wiley & Sons Ltd.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 11 January 2025
                : 02 May 2024
                : 17 January 2025
                Page count
                Figures: 4, Tables: 4, Pages: 17, Words: 11500
                Funding
                Funded by: Innovative Medicines Initiative 2 Joint Undertaking
                Award ID: 821283
                Funded by: European Union’s Horizon 2020 Research and Innovation Programme
                Funded by: EFPIA , doi 10.13039/100013322;
                Categories
                Original Article
                Original Article
                Custom metadata
                2.0
                March 2025
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.3 mode:remove_FC converted:06.02.2025

                Gastroenterology & Hepatology
                drug adverse reactions,drug toxicity,hepatotoxicity,liver injury
                Gastroenterology & Hepatology
                drug adverse reactions, drug toxicity, hepatotoxicity, liver injury

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content104

                Most referenced authors563